As the preclinical studies of the company have shown survival benefits in prostate cancer, the company now sees the product as a major commercial future in the rapidly evolving field of radioligand therapy.The company is confident that the products are capable of showing positive results not only in prostate cancer but also in other wide range of cancers. The company’s pre-clinical studies confirmed that the use of Veyonda in the LuPSMA therapy kills cancer causing cells.
The clinical studies were undertaken for 19.7 months with the LuPIN study combined with the Novartis drug. The company now positions the product as a major commercial future in the rapidly evolving field of radioligand therapy and believes that it will support the radioligand therapy market.
The company states that the LuPSMA had shown positive results but after adding Veyonda the pre-clinical trial results were more impressive as the tumours almost disappeared. Thus, the company see the successful trial results as a commercial opportunity. Many companies Noxopharm are developing drugs for killing cancer cells causing prostate cancer.